Acorda Therapeutics announced the U.S. Food and Drug Administration (FDA) approved INBRIJA for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa.....
Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration approved Inbrija™ for intermittent treatment of OFF episodes in people with ....
Acorda Therapeutics reported Thursday that the FDA extended its review of a filing seeking clearance of Inbrija (levodopa) by three months to January 5, 2019.